Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)
Phase 1
Terminated
- Conditions
- Brain MetastasesMalignant Melanoma
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Spirita Oncology, LLC
- Target Recruit Count
- 4
- Registration Number
- NCT03332589
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations
- First Posted Date
- 2015-04-16
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Spirita Oncology, LLC
- Target Recruit Count
- 27
- Registration Number
- NCT02418000
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸H. Lee Moffitt Cancer Center & research Institute, Tampa, Florida, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
News
No news found